Effect of Ramipril on the Incidence of Diabetes Academic Article uri icon

abstract

  • Previous studies have suggested that blockade of the renin-angiotensin system may prevent diabetes in people with cardiovascular disease or hypertension.In a double-blind, randomized clinical trial with a 2-by-2 factorial design, we randomly assigned 5269 participants without cardiovascular disease but with impaired fasting glucose levels (after an 8-hour fast) or impaired glucose tolerance to receive ramipril (up to 15 mg per day) or placebo (and rosiglitazone or placebo) and followed them for a median of 3 years. We studied the effects of ramipril on the development of diabetes or death, whichever came first (the primary outcome), and on secondary outcomes, including regression to normoglycemia.The incidence of the primary outcome did not differ significantly between the ramipril group (18.1%) and the placebo group (19.5%; hazard ratio for the ramipril group, 0.91; 95% confidence interval [CI], 0.81 to 1.03; P=0.15). Participants receiving ramipril were more likely to have regression to normoglycemia than those receiving placebo (hazard ratio, 1.16; 95% CI, 1.07 to 1.27; P=0.001). At the end of the study, the median fasting plasma glucose level was not significantly lower in the ramipril group (102.7 mg per deciliter [5.70 mmol per liter]) than in the placebo group (103.4 mg per deciliter [5.74 mmol per liter], P=0.07), though plasma glucose levels 2 hours after an oral glucose load were significantly lower in the ramipril group (135.1 mg per deciliter [7.50 mmol per liter] vs. 140.5 mg per deciliter [7.80 mmol per liter], P=0.01).Among persons with impaired fasting glucose levels or impaired glucose tolerance, the use of ramipril for 3 years does not significantly reduce the incidence of diabetes or death but does significantly increase regression to normoglycemia. (ClinicalTrials.gov number, NCT00095654 [ClinicalTrials.gov].).

authors

  • Bosch, J
  • Yusuf, S
  • Gerstein, HC
  • Pogue, J
  • Sheridan, P
  • Dagenais, G
  • Chiasson, JL
  • Diaz, R
  • Avezum, A
  • Lanas, F
  • Probstfield, J
  • Fodor, G
  • Holman, RR
  • Anand, S
  • Budaj, A
  • Conget, I
  • Davis, M
  • Dinccag, N
  • Enjalbert, M
  • Escalante, A
  • Hanefeld, M
  • Hedner, T
  • Jolly, K
  • Keltai, M
  • Laakso, M
  • Lonn, E
  • McQueen, M
  • Mohan, V
  • Phillips, A
  • Piegas, L
  • Pirags, V
  • Schmid, I
  • Shaw, J
  • Teo, K
  • Zimmet, P
  • Zinman, B
  • Ahuad Guerrero, R
  • Albisu, J
  • Alvarez, MS
  • Arregui, V
  • Avaca, H
  • Baglivo, H
  • Balbuena, M
  • Bello, F
  • Bono, J
  • Botto, M
  • Brandani, L
  • Brandes, M
  • Bruera, D
  • Cabral Venere, R
  • Caccavo, A
  • Cacurri, A
  • Caime, G
  • Capozzi, M
  • Carrique, A
  • Carrique, P
  • Cartasegna, L
  • Casabe, J
  • Casaccia, G
  • Castellanos, C
  • Castro, L
  • Cendali, G
  • Cerchi, P
  • Cerdan, M
  • Cinalli, M
  • Cipullo, M
  • Cismondi, M
  • Citta, N
  • Citta, L
  • Crespo, C
  • Crunger, P
  • Cuneo, C
  • De Loredo, L
  • De Loredo, S
  • Del Cerro, S
  • Denaro, R
  • Esperatti, E
  • Esposito, L
  • Farras, H
  • Fernandez, S
  • Fernandez, M
  • Fernandez, A
  • Ferrari, G
  • Focaccia, M
  • Frontini, L
  • Gabito, A
  • Gambarte, A
  • Garrido, M
  • Garrido, I
  • Guglielmotti, V
  • Hershson, A
  • Hoffman, V
  • Juarisit, G
  • Klyver, M
  • Lagrutta, M
  • Llanos, J
  • Liberman, A
  • Lobo Marquez, L
  • Lopez, R
  • Lowenstein, D

publication date

  • October 12, 2006